PCVX News and Press, Vaxcyte Inc. From 06/12/25

2025-06-12 10:10:00 ET PERFORMANCE RECAP The S&P 1500 Health Care Index (the Index) gained 0.9% in February, outperforming the S&P 500, which declined -1.3%. Biotechnology, health care technology, and pharmaceuticals outperformed the Index during the...

2025-06-11 11:19:00 ET Performance Average Annual Returns Read the full article on Seeking Alpha For further details see: Embark Small Cap Equity Fund Q1 2025 Commentary

2025-06-10 13:57:41 ET Today, I am putting Vaxcyte, Inc. ( PCVX ) in the spotlight for the first time since late 2023. I concluded my last article on this clinical stage vaccine stating the shares looked " fully valued" and declined any investment recommendation ...

2025-06-06 11:09:00 ET Performance Average Annual Returns Read the full article on Seeking Alpha For further details see: Harbor Health Care ETF Q1 2025 Commentary

2025-06-04 09:42:00 ET Summary During the first quarter, the Harbor Small Cap Growth Fund (Institutional Class, “Fund”) returned -10.45%, outperforming the Russell 2000® Growth Index, which returned -11.12%. Many of our top contributors were names that had weigh...

2025-05-31 00:20:00 ET Summary The equity portion of the Fund fell (gross of fees) and underperformed its benchmark, the NASDAQ Biotechnology Index. During the first quarter of 2025, we made several changes to the portfolio. With Donald Trump securing his second term, uncertai...

2025-05-30 09:05:00 ET Summary The equity portion of the Fund fell (gross of fees) and underperformed its benchmark over the quarter. During the first quarter of 2025, we made several changes to the portfolio. The top three detractors were Sarepta Therapeutics, Regeneron Pharm...

2025-05-28 12:16:00 ET Summary Small-cap stocks experienced a broad drawdown in Q1 with the Russell 2000® Growth Index (down 11.12%) trailing the Russell 2000® Value Index (down 7.74%) by a notable margin. Equity markets endured a painful first quarter as uncertainty sur...

2025-05-22 18:30:00 ET Summary In the first quarter, the Lazard US Equity Concentrated Portfolio underperformed its benchmark, the S&P 500 Index. The US equity market receded in the first quarter, as US tariff plans impacted outlooks for corporate spending and economic growth....

2025-05-20 16:15:00 ET Summary Janus Henderson Forty Fund returned -8.74% and the Russell 1000® Growth Index returned -9.97%. Stock selection in the consumer discretionary and financials sectors contributed to relative performance, while selection in information technology an...